A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections
The arthritogenic alphavirus, chikungunya virus (CHIKV), is now present in almost 100 countries worldwide. Further spread is very likely, which raises public health concerns. CHIKV infections cause fever and arthralgia, which can be debilitating and last for years. Here, we describe a CHIKV vaccine...
Saved in:
Main Authors: | Christin Schmidt (Author), Erik Haefner (Author), Julia Gerbeth (Author), Tim Beissert (Author), Ugur Sahin (Author), Mario Perkovic (Author), Barbara S. Schnierle (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chikungunya Vaccine Candidates: Current Landscape and Future Prospects
by: Schmidt C, et al.
Published: (2022) -
Identification of Functional Determinants in the Chikungunya Virus E2 Protein.
by: Christopher Weber, et al.
Published: (2017) -
A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice.
by: Christopher Weber, et al.
Published: (2015) -
Trans-amplifying RNA expressing functional miRNA mediates target gene suppression and simultaneous transgene expression
by: Ayşegül Yıldız, et al.
Published: (2024) -
Expression and Characterization of Yeast Derived Chikungunya Virus Like Particles (CHIK-VLPs) and Its Evaluation as a Potential Vaccine Candidate.
by: Shweta Saraswat, et al.
Published: (2016)